Properties (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Roche
|
| gptkbp:awards |
Fortune 100 Best Companies to Work For
Best Workplaces in Biotechnology |
| gptkbp:CEO |
gptkb:Alexander_Hardy
|
| gptkbp:clinicalTrials |
over 100 ongoing
focus on personalized medicine focus on monoclonal antibodies focus on gene therapy focus on biosimilars focus on biologics |
| gptkbp:communityEngagement |
volunteer programs
scholarship programs STEM education support employee matching gifts healthcare_access_initiatives |
| gptkbp:employees |
approximately 13,000
|
| gptkbp:founded |
1976
|
| gptkbp:founder |
gptkb:Herbert_W._Boyer
Robert_A._Swanson |
| gptkbp:headCoach |
over 13,000 employees
|
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Genentech Inc.
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:leadership |
sustainability initiatives
focus on innovation commitment to inclusion diverse executive team dedication to patient care |
| gptkbp:market |
$100 billion (2021)
|
| gptkbp:partnerships |
biopharmaceutical companies
various academic institutions |
| gptkbp:patentCitation |
over 1,000 patents filed
|
| gptkbp:philanthropy |
gptkb:Genentech_Foundation
community health initiatives education programs environmental sustainability initiatives |
| gptkbp:products |
gptkb:Avastin
Herceptin Lucentis Rituxan Xolair |
| gptkbp:researchFocus |
cancer
cardiology neurology autoimmune diseases ophthalmology |
| gptkbp:revenue |
$26.1 billion (2020)
|
| gptkbp:subsidiary |
gptkb:Roche_Holding_AG
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.gene.com
|